Calcitonin gene-related peptide-modulated macrophage phenotypic alteration regulates angiogenesis in early bone healing
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved..
OBJECTIVES: This study aimed to investigate the effect of calcitonin gene-related peptide (CGRP) on the temporal alteration of macrophage phenotypes and macrophage-regulated angiogenesis duringearlybonehealing and preliminarily elucidate the mechanism.
METHODS: In vivo, the rat mandibular defect models were established with inferior alveolar nerve transection (IANT) or CGRP receptor antagonist injection. Radiographicandhistologic assessments for osteogenesis, angiogenesis, and macrophage phenotypic alteration within bone defects were performed. In vitro, the effect and mechanism of CGRP on macrophage polarization and phenotypic alteration were analyzed. Then the conditioned medium (CM) from CGRP-treated M1 or M2 macrophages was used to culture human umbilical vein endothelial cells (HUVECs), and the CGRP's effect on macrophage-regulated angiogenesis was detected.
RESULTS: Comparable changes following IANT and CGRP blockade within bone defects were observed, including the suppression of early osteogenesis and angiogenesis, the prolonged M1 macrophage infiltration and the prohibited transition toward M2 macrophages around vascular endothelium. In vitro experiments showed that CGRP promoted M2 macrophage polarization while upregulating the expression of interleukin 6 (IL-6), a major cytokine that facilitates the transition from M1 to M2-dominant stage, in M1 macrophages via the activation of Yes-associated protein 1. Moreover, CGRP-treated macrophage-CM showed an anabolic effect on HUVECs angiogenesis compared with macrophage-CM and might prevail over the direct effect of CGRP on HUVECs.
CONCLUSIONS: Collectively, our results reveal the effect of CGRP on M1 to M2 macrophage phenotypic alteration possibly via upregulating IL-6 in M1 macrophages, and demonstrate the macrophage-regulated pro-angiogenic potential of CGRP in early bone healing.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
---|---|
Enthalten in: |
International immunopharmacology - 130(2024) vom: 30. März, Seite 111766 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kong, Qingci [VerfasserIn] |
---|
Links: |
---|
Themen: |
Angiogenesis |
---|
Anmerkungen: |
Date Completed 25.03.2024 Date Revised 27.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.intimp.2024.111766 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369421566 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369421566 | ||
003 | DE-627 | ||
005 | 20240329000712.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240308s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.intimp.2024.111766 |2 doi | |
028 | 5 | 2 | |a pubmed24n1353.xml |
035 | |a (DE-627)NLM369421566 | ||
035 | |a (NLM)38452411 | ||
035 | |a (PII)S1567-5769(24)00284-4 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kong, Qingci |e verfasserin |4 aut | |
245 | 1 | 0 | |a Calcitonin gene-related peptide-modulated macrophage phenotypic alteration regulates angiogenesis in early bone healing |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.03.2024 | ||
500 | |a Date Revised 27.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
520 | |a OBJECTIVES: This study aimed to investigate the effect of calcitonin gene-related peptide (CGRP) on the temporal alteration of macrophage phenotypes and macrophage-regulated angiogenesis duringearlybonehealing and preliminarily elucidate the mechanism | ||
520 | |a METHODS: In vivo, the rat mandibular defect models were established with inferior alveolar nerve transection (IANT) or CGRP receptor antagonist injection. Radiographicandhistologic assessments for osteogenesis, angiogenesis, and macrophage phenotypic alteration within bone defects were performed. In vitro, the effect and mechanism of CGRP on macrophage polarization and phenotypic alteration were analyzed. Then the conditioned medium (CM) from CGRP-treated M1 or M2 macrophages was used to culture human umbilical vein endothelial cells (HUVECs), and the CGRP's effect on macrophage-regulated angiogenesis was detected | ||
520 | |a RESULTS: Comparable changes following IANT and CGRP blockade within bone defects were observed, including the suppression of early osteogenesis and angiogenesis, the prolonged M1 macrophage infiltration and the prohibited transition toward M2 macrophages around vascular endothelium. In vitro experiments showed that CGRP promoted M2 macrophage polarization while upregulating the expression of interleukin 6 (IL-6), a major cytokine that facilitates the transition from M1 to M2-dominant stage, in M1 macrophages via the activation of Yes-associated protein 1. Moreover, CGRP-treated macrophage-CM showed an anabolic effect on HUVECs angiogenesis compared with macrophage-CM and might prevail over the direct effect of CGRP on HUVECs | ||
520 | |a CONCLUSIONS: Collectively, our results reveal the effect of CGRP on M1 to M2 macrophage phenotypic alteration possibly via upregulating IL-6 in M1 macrophages, and demonstrate the macrophage-regulated pro-angiogenic potential of CGRP in early bone healing | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Angiogenesis | |
650 | 4 | |a Bone regeneration | |
650 | 4 | |a Calcitonin gene-related peptide | |
650 | 4 | |a Interleukin-6 | |
650 | 4 | |a Macrophage | |
650 | 4 | |a YAP1 protein | |
650 | 7 | |a Calcitonin Gene-Related Peptide |2 NLM | |
650 | 7 | |a JHB2QIZ69Z |2 NLM | |
650 | 7 | |a Interleukin-6 |2 NLM | |
700 | 1 | |a Gao, Siyong |e verfasserin |4 aut | |
700 | 1 | |a Li, Pugeng |e verfasserin |4 aut | |
700 | 1 | |a Sun, Hanyu |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Zhengchuan |e verfasserin |4 aut | |
700 | 1 | |a Yu, Xiaolin |e verfasserin |4 aut | |
700 | 1 | |a Deng, Feilong |e verfasserin |4 aut | |
700 | 1 | |a Wang, Tianlu |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 130(2024) vom: 30. März, Seite 111766 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
773 | 1 | 8 | |g volume:130 |g year:2024 |g day:30 |g month:03 |g pages:111766 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2024.111766 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 130 |j 2024 |b 30 |c 03 |h 111766 |